Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Erector Spinae Plane Block Versus External Oblique Intercostal Plus Lateral External Oblique Muscle Plane Block in Laparoscopic Living Donor Nephrectomy

12. november 2026 oppdatert av: Ayse Ince, Istanbul Medipol University Hospital

Comparison of Erector Spinae Plane Block and Combined External Oblique Intercostal and Lateral External Oblique Muscle Plane Blocks for Postoperative Analgesia After Laparoscopic Living Donor Nephrectomy: A Prospective, Randomized, Double-Blind Trial

Living kidney donors undergoing laparoscopic donor nephrectomy will be randomized to receive either an erector spinae plane block (ESPB) or a combination of external oblique intercostal (EOI) and lateral external oblique muscle plane (lateral EXOP) blocks at the end of surgery. The study aims to compare postoperative pain scores, opioid consumption, rescue analgesic requirement and postoperative nausea and vomiting between the two groups.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Laparoscopic living donor nephrectomy is associated with less postoperative pain than open surgery; however, trocar sites, the extraction incision and flank dissection can still cause substantial somatic and visceral pain. Results regarding the analgesic efficacy of ESPB in laparoscopic donor nephrectomy are conflicting, and sensory spread to the anterolateral abdominal wall after ESPB appears variable. The EOI block targets the lateral and anterior cutaneous branches of the T6-T10 intercostal nerves, and the lateral EXOP block targets the lateral cutaneous branches of T11-T12. As the trocar sites and the extraction incision are located on the anterolateral abdominal wall, we hypothesize that the combination of EOI and lateral EXOP blocks may provide more consistent analgesia than ESPB.

All donors will undergo transperitoneal laparoscopic donor nephrectomy, and the kidney will be extracted through the lower lateral trocar site as standard. Anesthesia will be induced with propofol, fentanyl and rocuronium and maintained with sevoflurane and remifentanil. Thirty minutes before the end of surgery, all patients will receive 1 g IV paracetamol, 100 mg IV tramadol and 8 mg IV ondansetron.

All blocks will be performed unilaterally on the surgical side under ultrasound guidance, after skin closure and before emergence from anesthesia, with the patient in the surgical lateral decubitus position. Each group will receive a total of 40 mL of 0.25% bupivacaine.

Group ESPB: the block will be performed at the T9 level, 2-3 cm lateral to the spinous process, with 40 mL of 0.25% bupivacaine injected deep to the erector spinae muscle.

Group EOI + lateral EXOP: the EOI block will be performed at the 6th rib level between the midclavicular and anterior axillary lines, with 20 mL of 0.25% bupivacaine injected between the external oblique and intercostal muscles. The lateral EXOP block will be performed on the mid-axillary line between the costal margin and the iliac crest, with 20 mL of 0.25% bupivacaine injected superficial to the external oblique muscle.

Postoperatively, all patients will receive 1 g IV paracetamol every 8 hours and fentanyl via IV patient-controlled analgesia (10 µg bolus, 10-minute lockout, no background infusion). Patients with NRS ≥4 despite PCA use will receive 0.5 mg/kg IV pethidine as rescue analgesia.

Because all blocks will be performed under general anesthesia, patients will be unaware of their group allocation. To maintain blinding, a standard dressing will be applied to all three potential block sites (paravertebral at T9, 6th rib level and lateral abdomen) in every patient. All postoperative assessments will be performed by an independent anesthesiologist who is not involved in block administration and is blinded to group allocation.

Studietype

Intervensjonell

Registrering (Antatt)

70

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Living kidney donors aged 18-65 years ASA physical status I-II Scheduled for elective pure transperitoneal laparoscopic donor nephrectomy Written informed consent

Exclusion Criteria:

Chronic pain or chronic opioid use Infection at the block site Allergy to local anesthetics Coagulopathy or anticoagulant use Body weight <50 kg Pregnancy Inability to use the NRS or PCA device Refusal to participate

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Group ESPB

Unilateral ultrasound-guided ESPB at T9 on the surgical side with 40 mL of 0.25% bupivacaine, performed at the end of surgery before emergence.

Unilateral ultrasound-guided erector spinae plane block performed on the surgical side at the T9 level after skin closure and before emergence from general anesthesia, with the patient in the lateral decubitus position. A linear probe will be placed 2-3 cm lateral to the spinous process in a parasagittal orientation. The needle will be advanced in-plane in a cranio-caudal direction until its tip lies between the erector spinae muscle and the transverse process. After hydrodissection with 5 mL of saline, 40 mL of 0.25% bupivacaine will be injected.

Andre navn:
  • ESPB
  • ESP-blokk

All patients will receive 1 g IV paracetamol and 100 mg IV tramadol 30 minutes before the end of surgery. Postoperatively, 1 g IV paracetamol will be given every 8 hours, and fentanyl will be delivered via IV patient-controlled analgesia (10 µg bolus, 10-minute lockout, no background infusion). Patients with NRS ≥4 despite PCA will receive 0.5 mg/kg IV pethidine as rescue analgesia.

Andre navn:
  • Paracet
  • Tramadol
  • Fentanyl IV PCA
Eksperimentell: Group EOI and Lateral EXOP Combination

External oblique intercostal block and lateral external oblique muscle plane block combination will be applied. Unilateral ultrasound-guided EOI block at the 6th rib level (20 mL of 0.25% bupivacaine) and lateral EXOP block (20 mL of 0.25% bupivacaine) on the surgical side, performed at the end of surgery before emergence.

All patients will receive 1 g IV paracetamol and 100 mg IV tramadol 30 minutes before the end of surgery. Postoperatively, 1 g IV paracetamol will be given every 8 hours, and fentanyl will be delivered via IV patient-controlled analgesia (10 µg bolus, 10-minute lockout, no background infusion). Patients with NRS ≥4 despite PCA will receive 0.5 mg/kg IV pethidine as rescue analgesia.

Andre navn:
  • Paracet
  • Tramadol
  • Fentanyl IV PCA

Unilateral ultrasound-guided blocks will be performed on the surgical side after skin closure and before emergence from general anesthesia. EOI block: the probe will be placed at the 6th rib level between the midclavicular and anterior axillary lines in a paramedian sagittal-oblique orientation, and 20 mL of 0.25% bupivacaine will be injected between the external oblique and intercostal muscles. Lateral EXOP block: the probe will be placed on the mid-axillary line between the costal margin and the iliac crest, and 20 mL of 0.25% bupivacaine will be injected superficial to the external oblique muscle. Correct needle tip position is confirmed with 5 mL of saline before each injection. Total volume: 40 mL of 0.25% bupivacaine.

Andre navn:
  • EOI block
  • Lateral EXOP block

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pain score at 8th hour
Tidsramme: 8 hours after PACU admission

Pain intensity at rest assessed with the Numeric Rating Scale (0 = no pain, 10 = worst imaginable pain)

8 hours after PACU admission

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cumulative fentanyl consumption
Tidsramme: 0-24 hours postoperatively

Total fentanyl given via IV PCA (µg).

0-24 hours postoperatively
Pain scores at rest and on coughing
Tidsramme: 0, 2, 4, 8, 12 and 24 hours postoperatively.

Pain scores at rest and on coughing will be recorded based on NRS (0-10).

0, 2, 4, 8, 12 and 24 hours postoperatively.
Time to first rescue analgesic
Tidsramme: 0-24 hours postoperatively.

Time from PACU admission to the first pethidine dose given for NRS ≥4.

0-24 hours postoperatively.
Incidence of postoperative nausea and vomiting.
Tidsramme: 0-24 hours postoperatively.

Number of patients with any nausea or vomiting episode will be recorded.

0-24 hours postoperatively.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

15. desember 2026

Primær fullføring (Antatt)

15. januar 2028

Studiet fullført (Antatt)

15. januar 2028

Datoer for studieregistrering

Først innsendt

12. november 2026

Først innsendt som oppfylte QC-kriteriene

12. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • Medipol 9

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

There is no plan to make individual participant data available

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .